Risk Factors of Chronic Kidney Disease-related Sarcopenia and Its Relationship With Poor Prognosis
Overview
- Phase
- Not Applicable
- Intervention
- No intervention
- Conditions
- Chronic Kidney Diseases
- Sponsor
- Nanfang Hospital, Southern Medical University
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- sarcopenia
- Status
- Recruiting
- Last Updated
- 26 days ago
Overview
Brief Summary
Chronic kidney disease (CKD) has become a global public health priority over the past few decades, affecting 10-12% of the adult population and has received increasing attention. Sarcopenia describes a generalizes degenerative skeletal muscle disorder involving the loss of muscle mass, muscle function and/or physical performance. Indeed, Sarcopenia is a condition with many causes and it can be considered "primary sarcopenia" when no other cause is evident but ageing. While in the clinical practice, it also occurs in patients with chronic diseases, such as chronic kidney disease, which can be considered "secondary sarcopenia". Notably, the occurrence of sarcopenia in CKD patients is not only related with ageing, the accumulation of uremic toxins, inflammation, insulin resistance, malnutrition and oxidative stress also contribute to the muscle depletion. Moreover, sarcopenia increased risk of falls and fractures, impaired ability to perform activities of daily living, disabilities, loss of independence and increased risk of death. Hence, it is of great significance to prevent the occurrence and development of sarcopenia in patients with CKD. The purposes of this project were to investigate the prevalence of sarcopenia, further explore the risk factors for sarcopenia and detect the relationship between sarcopenia and outcomes in CKD patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1.aged ≥18 years and \<80 years 2.eGFR\<60ml/min/1.73m2 or had received maintenance dialysis for at least 3 months.
Exclusion Criteria
- •1.Patients with neuromuscular diseases: such as muscular dystrophy, amyotrophic lateral sclerosis, spinal cord injury, stroke, and myasthenia gravis; 2.Patients with neurodegenerative diseases: such as Alzheimer's disease, Parkinson's disease and Huntington's disease; 3.patients with advanced malignant tumors; 4.Patients with acute infectious diseases in the past 3 months;
- •Patients with serious cardiovascular or cerebrovascular disease; 6.Moderate to severe edema; 7.Patients with rheumatoid arthritis, multiple sclerosis, or acute gout that limit joint mobility; 8.Pregnant ; 9.Patients identified to be unsuitable for enrollment by the study physician
Arms & Interventions
chronic kidney disease
Intervention: No intervention
maintenance hemodialysis
Intervention: No intervention
Outcomes
Primary Outcomes
sarcopenia
Time Frame: 1 year
The sarcopenia is defined as: Patients with low strength: handgrip \<28kg for male or \<18kg for female; Or low muscle mass: appendicular skeletal muscle mass/height2 \<7kg/m2 for male or \<5.7kg/m2 for female; Or low performance: 6-metre walk: \<1.0 m/s or 5-time chair stand test: ≥12 s
The progression of chronic kidney diseases in CKD patients
Time Frame: 1 year
The progression of chronic kidney disease is defined as: Patients had a 50% or greater decrease in baseline eGFR \<60 ml /min/1.73m2; Or end-stage renal disease (eGFR \<15 ml /min/1.73m2, or initiation of renal replacement therapy)
All-cause mortality in maintenance hemodialysis patients
Time Frame: 1 year
All-cause mortality is defined as the death due to any reasons.
Secondary Outcomes
- cardiovascular events(1 year)
- Rate of participants with hospitalization.(1 year)
- Rate of participants with fall.(1 year)
- CVD mortality(1 year)
- Rate of participants with bone fracture.(1 year)
- Change of quality of life(1 year)
- Frailty(1 year)